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Strengths and limitations of this study
 ► An integrated approach consisting of parallel 
non- invasive techniques assessing multiple hae-
modynamic parameters will compile extensive hae-
modynamic profiles of participants.
 ► Haemodynamic adaptation to pregnancy will be 
measured prospectively from the preconception 
period onwards to 3 months postdelivery, thereby 
covering an important window in the reproductive 
timespan.
 ► Simultaneous assessment of maternal haemody-
namic adaptation to pregnancy and uteroplacental 
vascular development will provide new insights into 
the interaction between both mechanisms and the 
pathophysiology of pregnancy complications.
 ► Since only multiparous women will be included, 
conclusions about whether maternal haemodynamic 
maladaptation is a cause or consequence of previ-
ous pregnancy outcome cannot be provided.
ABSTRACT
Introduction The importance of cardiovascular 
health in relation to pregnancy outcome is increasingly 
acknowledged. Women who develop certain pregnancy 
complications, in particular preeclampsia, are at higher 
risk for future cardiovascular disease. Independent of 
its outcome, pregnancy requires a substantial adaptive 
response of the maternal cardiovascular system. In the 
Hemodynamic Adaptation to Pregnancy and Placenta- 
related Outcome (HAPPO) study, we aim to examine 
longitudinal maternal haemodynamic adaptation to 
pregnancy from the preconception period onwards. 
We hypothesise that women who will develop adverse 
pregnancy outcomes have impaired cardiovascular 
health before conception, leading to haemodynamic 
maladaptation to pregnancy and diminished uteroplacental 
vascular development.
Methods and analysis In this prospective cohort study 
embedded in the Rotterdam periconception cohort, 200 
women with a history of placenta- related pregnancy 
complications (high- risk group) and 100 women with an 
uncomplicated obstetric history (low- risk group) will be 
included. At five moments (preconception, first, second 
and third trimester and postdelivery), women will undergo 
an extensive examination of the macrocirculatory and 
microcirculatory system and uteroplacental vascular 
development. The main outcome measures are differences 
in maternal haemodynamic adaptation to pregnancy 
between women with and without placenta- related 
pregnancy complications. In a multivariate linear mixed 
model, the relationship between maternal haemodynamic 
adaptive parameters, (utero)placental vascularisation 
indices and clinical outcomes (occurrence of pregnancy 
complications, embryonic and fetal growth trajectories, 
miscarriage rate, gestational age at delivery, birth weight) 
will be studied. Subgroup analysis will be performed to 
study baseline and trajectory differences between high-
risk and low- risk women, independent of subsequent 
pregnancy outcome.
Ethics and dissemination This study protocol was 
approved by the Medical Ethics Committee of the Erasmus 
MC, Rotterdam, the Netherlands (MEC 2018–150). Results 
will be disseminated to the medical community by 
publications in peer- reviewed journals and presentations 
at scientific congresses. Also, patient associations will be 
informed and the public will be informed by dissemination 
through (social) media.
Trial registration number NL7394 ( www. trialregister. nl)
InTRoduCTIon
Context
Placenta- related pregnancy complications 
(PPC), such as preeclampsia and/or fetal 
growth restriction (FGR), occur in approxi-
mately 10%–15% of all pregnancies.1–3 PPC 
affect perinatal morbidity and mortality and 
significantly impact the long- term cardio-
vascular health of women and their chil-
dren with associated healthcare costs for 
society.4–6 For example, women with a history 
of preeclampsia have a twofold to seven-
fold increased risk to develop ischaemic 
heart disease in later life, depending on the 
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Figure 1 Schematic hypothesis: Is haemodynamic 
maladaptation to pregnancy the missing link in the aetiology 
of placenta- related pregnancy complications?
gestational age and severity at onset of preeclampsia.4 
Thus, early identification of women who are at risk for 
PPC is important to enable subsequent personalised 
prevention and treatment strategies in order to improve 
reproductive outcome and to improve lifelong cardio-
vascular health. To date, most available screening tests 
for adverse pregnancy outcome use blood pressure and 
uterine artery blood flow, which reflect the haemody-
namic profile of the mother and thereby the likelihood of 
impaired placental development and subsequent adverse 
events. Nonetheless, these markers are not directly related 
to cardiac or placental function, which may explain the 
moderate predictive performances of most prognostic 
models.7 8
Haemodynamic adaptation to pregnancy
Pregnancy requires a physiological adaptive response 
of the maternal cardiovascular system with a substantial 
rise in plasma volume and cardiac output (CO).9 Already 
in the first trimester of pregnancy, a woman’s systemic 
vascular resistance decreases with 35%–40% and her 
stroke volume increases with 8%.9 This natural volume 
overload leads to a reversible, physiological left ventric-
ular dilatation and a possible change in left ventricular 
diastolic function.10 In most pregnancies, these changes 
occur without clinical problems. However, in women 
who develop PPC, maternal haemodynamic adaptation 
can be different and diastolic dysfunction is more often 
present.11 12
Moreover, in women with complicated pregnancies, 
endothelial dysfunction and increased vascular stiffness 
are also more common.13 14 The endothelial lining of the 
vasculature in the human body is of great importance in 
the regulation of vascular tone. Vascular stiffness increases 
during normal ageing by the replacement of elastin fibres 
with less elastic collagen. Endothelial function tests and 
arterial vascular stiffness measurements have already 
proven to be of importance in predicting cardiovascular 
disease.15
Together, this all supports the hypothesis that in women 
who develop PPC an increased risk for cardiovascular 
disease is unmasked by the stressed state of pregnancy.16 17 
However, knowledge on maternal haemodynamic adap-
tation to pregnancy, as early as the time of conception, is 
scarce and often only focuses on one or two parameters 
instead of the complex interaction between macrocircula-
tory and microcirculatory parameters. Only a few studies 
starting prior to pregnancy have shown haemodynamic 
changes in, for example, blood pressure, heart rate and 
CO early in pregnancy.18–22 An integrated approach using 
parallel techniques and multiple haemodynamic parame-
ters from the preconception period onwards throughout 
pregnancy is needed to provide insight in individual 
(patho)physiological haemodynamic adaptation to 
pregnancy.
Placental development and function
The adequate establishment of the maternal–fetal 
vascular interface early in gestation is essential for a 
healthy pregnancy outcome. Among others, this requires 
adaptation of the uterine spiral arteries into remodelled 
vessels to create a low- resistance uteroplacental circula-
tion.23 24 Failure in the adaptation of the uterine vascula-
ture causes hypoperfusion of the placenta and is widely 
believed to underlie several pregnancy complications.25 26 
This is substantiated by several changes in histopathology, 
including decidual vasculopathy, villous hypoplasia and 
lesions consistent with loss of integrity of the vascular 
wall of the maternal circulation in delivered placentas 
of women with PPC.27–29 However, the aetiology of these 
placental abnormalities and its relation with maternal 
cardiovascular health remains unclear.
RESEARCH HyPoTHESIS And AIM
We hypothesise that impaired maternal cardiovascular 
health leads to haemodynamic maladaptation to preg-
nancy, diminished uteroplacental vascular development 
and subsequent pregnancy complications (figure 1). The 
overall aim of the Hemodynamic Adaptation to Preg-
nancy and Placenta- related Outcome (HAPPO) study is to 
examine associations between maternal haemodynamic 
adaptation to pregnancy and (utero)placental vascular 
development in women with and without (a history of) 
pregnancy complications. Therefore, we specified the 
following objectives:
1. To assess haemodynamic parameters before, during 
and after pregnancy to gain insight in (patho)
physiological maternal haemodynamic adaptation 
mechanisms.
2. To assess longitudinal utero(placental) vasculature 
development using state- of- the- art three- dimensional 
ultrasound and Virtual Reality techniques combined 
with in vivo examination of placental bed biopsies.
3. To construct a multivariate model to study the associ-
ations between maternal haemodynamic adaptation 
to pregnancy, utero(placental) vascular development 
and PPC.
4. To study differences in baseline haemodynamic pa-
rameters and haemodynamic adaptation to pregnancy 
between women with and without a history of PPC.
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Table 1 Inclusion and exclusion criteria for participants in 
the HAPPO study
Inclusion 
criteria
 ► Minimum age of 18 years
 ► Delivery date of last pregnancy more than 
1 year ago
 ► Previous pregnancy complicated by PPC or 
uncomplicated previous pregnancy
 ► Current wish to become pregnant
Exclusion 
criteria
 ► Unable or unwilling to provide informed 
consent
 ► Currently breastfeeding
HAPPO, Hemodynamic Adaptation to Pregnancy and Placenta- 
related Outcome; PPC, placenta- related pregnancy complications.
Figure 2 Overview of study visits and examinations to establish cardiovascular function and utero(placental) vascular 
development from before conception until after delivery. CPET, cardiopulmonary exercise test; ICG, impedance cardiography; 
PORH, postocclusion reactive hyperaemia; US, ultrasound.
STudy dESIgn
The HAPPO study is a single- centre prospective cohort 
study, embedded in the ongoing Rotterdam periconcep-
tion cohort, performed at the department of Obstetrics 
and Gynaecology of the Erasmus MC, University Medical 
Centre Rotterdam, the Netherlands.30
STudy PoPulATIon
We aim to include 200 women with a history of preg-
nancy complications (ie, preeclampsia and/or FGR). 
Preeclampsia is defined according to the American 
College of Obstetricians and Gynecologists (ACOG) 
criteria and FGR is defined conform the Delphi consensus 
definition described by Gordijn et al.1 31
Also, 100 women after uncomplicated pregnancies and 
(term) deliveries will be included as a low- risk control 
group. Women are eligible to participate in this study 
when they have a minimum age of 18 years, the delivery 
date of their last pregnancy was more than 1 year ago, they 
have a current wish to become pregnant and the previous 
pregnancy was either complicated by PPC or the previous 
pregnancy was uncomplicated. Women who are unable or 
unwilling to provide informed consent will be excluded 
from participation. Also, if a woman is currently breast-
feeding, she will be excluded from participation since this 
may influence her vascular condition. The inclusion and 
exclusion criteria are shown in table 1.
STudy PRoCEduRES/MEASuREMEnTS
An overview of all study procedures is provided in figure 2. 
The first study visit will be planned when the participating 
woman has the wish to become pregnant, but before 
conception takes place. When a pregnancy occurs within 
1 year, a study visit will be planned in each trimester as 
well as 3 months postdelivery, which will be the last study 
visit. All communication with the participants is coordi-
nated by one researcher (RCB) who also performs all 
study procedures during the study visits.
Questionnaires
Participants of the study will receive a total of three 
questionnaires: (1) after the preconceptional study visit, 
participants will receive an online questionnaire on 
demographic characteristics, medical conditions and life-
style; (2) preceding the study visit in the first trimester of 
pregnancy, participants will receive an online question-
naire to address possible changes in medical conditions 
and lifestyle; (3) after delivery, participants will receive an 
online follow- up questionnaire on pregnancy and birth 
outcomes (ie, gestational age at birth, mode of delivery, 
birth weight, neonatal sex, pregnancy and/or delivery 
complications). During the postdelivery visit, the partic-
ipants will, among others, be asked about current breast-
feeding and smoking habits.
Anthropometrics
At each visit, a woman’s height, weight, hip and waist 
circumference will be measured using standardised, vali-
dated methods to compose the classical cardiovascular 
risk factors body mass index and waist- to- hip ratio.32
Blood sample
Two blood samples (8.5 mL serum tube and 10 mL EDTA 
tube) will be obtained at the preconception visit, the first- 
trimester and third- trimester visit and the postdelivery 
visit. All samples will be centrifuged and divided into 
aliquots of serum, plasma, whole blood and buffy coat 
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and then stored in a −80°C freezer at the trial laboratory 
at our own facility for future assessment of cardiovascular 
markers (eg, C reactive protein and lipids) and markers 
of placental function (eg, PlGF and sFlt-1).
Echocardiography
Transthoracic echocardiography has become the prefer-
ential method for safe, non- invasive cardiac assessment 
in pregnant women.33 34 At all study visits, echocardiog-
raphy will be performed using an Affiniti 70G ultrasound 
machine (Philips Healthcare, Andover, USA) by a trained 
researcher (RCB) under the supervision of a cardiolo-
gist (AEB). Echocardiograms will be fulfilled according 
to the recommendations of the European Association of 
Cardiovascular imaging.35 CO will be derived from the left 
ventricle outflow tract (LVOT) velocity time integral and 
LVOT cross- sectional area. From this, systemic vascular 
resistance will be calculated (ie, mean blood pressure 
divided by CO). Left ventricular diastolic function will be 
assessed by mitral inflow (E/A) and tissue Doppler (E/e’) 
examination. Global left ventricular systolic function will 
be assessed by using the Teichholz method for ejection 
fraction calculation.36
Postocclusion reactive hyperaemia
One of the first manifestations of an impaired cardiovas-
cular risk profile is endothelial dysfunction of small vessels 
(microcirculation). Postocclusion reactive hyperaemia 
will be used in this study to assess the endothelial function 
of the peripheral microvasculature. We use devices from 
Moor instruments (moorVMS- VASC 2.0, moorVMS- PRES 
and moorVMS- LDF; Axminster, UK) to measure microvas-
cular blood flow reactivity following arterial occlusion by 
using a non- invasive laser Doppler flowmetry (LDF) tech-
nique. In resting position, after 3 min of arterial occlusion 
by a cuff surrounding the upper left arm, the reperfusion 
of microvascular blood in the skin is measured by the LDF 
skin probe which is attached to the lower arm. The peak 
response after the release of the occlusion and the time 
to recover to baseline reflect endothelial regulated micro-
vascular function.37 38
Pulse wave analysis
A cuff- based oscillometric device (Mobil- O- Graph PWA by 
I.E.M., Stolberg, Germany) will be used to assess central 
and peripheral blood pressure, pulse wave velocity and 
augmentation index (AIx).39 40 Pulse wave velocity values 
are derived from an algorithm which integrates age, 
central systolic blood pressure and data derived from 
pulse wave analysis into a mathematical model.41 Higher 
values of pulse wave velocity indicate higher arterial 
stiffness and thus a worse vascular condition. The AIx 
provides additional information on the stiffness of the 
aorta and is derived from the central pressure waveform.
Cardiopulmonary exercise test with bioimpedance 
cardiography
To assess the haemodynamic response during physical 
stress, CO will also be measured using signal morphology 
impedance cardiography (SM- ICG) using PhysioFlow 
PF07 Enduro (Manatec biomedical, Poissy, France). The 
exercise during which the SM- ICG will be performed is a 
cardiopulmonary exercise test on a cycle ergometer with a 
RAMP protocol to 70% of the estimated maximum heart 
rate according to the Tanaka formula.42 Moderate exer-
cise limited to 70% of the maximal heart rate is consid-
ered safe during pregnancy.43
uteroplacental vascularisation measurements
Studies using conventional two- dimensional Doppler 
ultrasound have shown that increased vascular resistance 
of the uterine arteries is associated with an increased risk 
for subsequent development of PPC.7 44 Therefore, pulsed 
wave Doppler measurements of the right and left uterine 
artery will be performed at all study visits to provide the 
pulsatility and resistance indices. Moreover, to evaluate 
the morphology of the uterine and placental vasculature 
and quantification of perfusion, a 3D power Doppler scan 
of the uterine (preconception visit) and placental bed 
(first- trimester visit) vasculature will be performed, also 
using the Affiniti 70G ultrasound machine. By assessing 
these 3D datasets in an innovative virtual reality system 
(Barco I- Space or 3D desktop), depth perception and 
three- dimensional interaction enables more accurate and 
detailed quantification of the utero(placental) vascular 
volumes. At the Erasmus MC, there is extensive experi-
ence with this novel technology and the uteroplacental 
vascular volume measurements have proven to be feasible 
and reliable.45 46
With respect to the risks of performing ultrasound 
examinations in the first trimester using 3D power 
Doppler, recommendations as set by the International 
Society of Ultrasound in Obstetrics and Gynaecology 
(ISUOG) are followed for the purpose of this study (ie, 
thermal index ≤1.0, mechanical index <1.9 and total 
exposure time <10 min). Transvaginal scanning time 
(preconception and first trimester) and transabdominal 
scanning time (second and third trimester) will be kept 
as short as possible according to the as low as reasonably 
achievable (ALARA) principles.47 48
Embryonic and fetal growth parameters
At the first trimester visit, additional parameters of embry-
onic growth will be measured, that is, crown- rump length 
and embryonic volume. The obtained 3D datasets will be 
visualised in the Barco I- Space or desktop version and 
offline volume measurements will be performed.
At the second and third trimester visit, additional 
parameters of fetal growth (head circumference, abdom-
inal circumference, femur length) and pulsed wave 
Doppler measurements of the umbilical artery and 
median cerebral artery will be performed by transabdom-
inal ultrasound.
Placental examinations
At delivery, histological samples of in vivo placental vascu-
lature will be harvested. The placenta will be collected 
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according to standard procedures and four samples of 
approximately 3 cm × 3 cm are then fixated in 4% para-
formaldehyde for storage. The fixated placenta biopsies 
will be processed and studied as done in routine placental 
pathology examination.
In a subgroup of women who undergo a caesarean 
section (estimated 30% of our study population) at the 
Erasmus MC, four punch biopsies of the placental bed 
will be collected, which consist of decidual and myome-
trial tissue and contain spiral arteries.49 The samples are 
directly rinsed with sterile NaCl to wash excessive blood 
and then fixated in 4% paraformaldehyde for storage 
and examination. According to our previously published 
protocol, several markers will be used to score the devel-
opmental state of the spiral arteries, identifying typical 
acute atherosis lesions and evaluating involvement of the 
immune system.49 50
ouTCoME MEASuRES
The primary outcome measure of the HAPPO study is 
the difference in maternal haemodynamic adaptation to 
pregnancy, expressed as the trajectory of CO assessed by 
echocardiography before, during and after pregnancy, 
between women who do and do not develop PPC. CO 
is one of the most frequently described haemodynamic 
parameters in pregnancy, alongside with blood pressure. 
By using transthoracic echocardiography, as a validated 
and safe method to measure CO, we will obtain consecu-
tive and reliable information on maternal haemodynamic 
adaptation to pregnancy.34
The secondary outcome measures are differences in 
additional indices of maternal haemodynamic adaptation 
to pregnancy and utero(placental) vascular development 
between women who do and do not develop PPC. This 
includes differences in weight gain during pregnancy, 
blood pressure, systemic vascular resistance, left ventric-
ular diastolic function, endothelial regulated micro-
vascular function, pulse wave analysis, haemodynamic 
response to exercise, placental vascular indices, fetal 
growth parameters (including Doppler measurements) 
and placenta/placental bed pathology examinations.
SAMPlE SIzE CAlCulATIon
Since we aim to investigate multiple haemodynamic 
parameters and literature on this subject is scarce, sample 
sizes are difficult to calculate. There are a few studies that 
describe the longitudinal trajectory of CO from precon-
ception until after delivery in uncomplicated pregnancies 
and a couple of cross- sectional studies that investigated CO 
in either the first of third trimester of pregnancy.18–20 51 52 
Based on these studies, we expect a difference of approxi-
mately 0.5 SD at each time point and an intraclass correla-
tion coefficient of at least 0.3 between time points in our 
study. With alpha set at 0.05 and a power of 0.8, simulation 
for linear mixed model analysis based on these estimates 
showed that 38 cases (PPC in the anticipated pregnancy) 
are needed to establish such differences.53
Based on literature, we expect a 25% recurrence rate 
of PPC in the high- risk group and a 2% incidence of PPC 
in the low- risk group.54–56 Thus, PPC cases will primarily 
occur in the high- risk group. For an expected number of 
38 cases, we would need to follow- up 38/0.25=152 preg-
nancies in the high- risk group.
Multiparous women who wish to become pregnant who 
are actively contemplating pregnancy are assumed to 
have an approximately 85% chance to become pregnant 
again within 1 year.57 58 The overall miscarriage rate in this 
study group is estimated to be approximately 10%.59 With 
this taken into account, we would need to include 152/ 
(0.85*0.90)=198 high- risk women prior to conception. 
For comparison with women at low risk for PPC and to 
increase the number of controls, we will also include 100 
low- risk women with an uncomplicated previous preg-
nancy. With this sample size, we expect, based on previous 
research, to be able to detect differences of approxi-
mately 5%–10% in other haemodynamic parameters and 
utero(placental) vasculature development (secondary 
outcomes).11 14 18 51 60–66
STATISTICAl AnAlySIS PlAn
Patient characteristics, medical conditions and life-
style data will be presented as means (SD) or numbers 
(percentage) and compared using t- tests and χ² tests. 
Haemodynamic parameters will be presented as means 
(SD) at each time point and compared between groups 
using t- tests.
Multivariate linear mixed models will be used to analyse 
the trajectories of maternal haemodynamic parame-
ters over time. We will test whether there is a difference 
between women who do and do not develop PPC by 
comparing each trajectory using a likelihood ratio test.
Subgroup analyses will be performed to study (baseline 
and trajectory) differences between high- risk and low- risk 
women, independent of subsequent pregnancy outcome. 
Bonferroni corrections will be applied to control for 
multiplicity of secondary outcome parameters.
In case of significant differences in patient characteris-
tics between groups, regression analyses will be adjusted 
for these characteristics.
dATA CollECTIon, HAndlIng And SToRAgE
The study will be performed according to written 
informed consent procedures which ensures personal 
data protection and confidentiality. Data will be deiden-
tified (pseudoanonymised) in order to guarantee the 
privacy of the participants, and the key to the code will be 
safeguarded by the investigators and will remain on site 
with the local research team.
All research data will be retained and stored in the 
HAPPO- database at a secured server at the research insti-
tution and it will remain there for at least 15 years after 
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completion of the project. All imaging data will be stored 
and handled in the same way and according to the same 
rules and regulations as other patient- related imaging 
data at Erasmus MC.
Monitoring of data and safety will be performed once a 
year, according to local protocol for research with negli-
gible risk.
PATIEnT And PuBlIC InvolvEMEnT
Patient and public were not involved in the design of the 
study. However, at the earliest moment of recruitment, 
two large patient associations for women who experi-
enced PE and/or HELLP syndrome (ie, HELLP Stichting 
(http://www. hellp. nl) and the Preeclampsia Foundation 
(http://www. preeclampsia. org)) were informed and are 
involved in promoting the HAPPO study.
ETHICS And dISSEMInATIon
The study will be conducted according to the principles 
of the Declaration of Helsinki (version October 2013) 
and in accordance with relevant national guidelines, 
regulations and Acts (eg, the Medical Research Involving 
Human Subjects Act (WMO)). The study protocol 
was approved by the Medical Ethics Committee of the 
Erasmus MC (MEC-2018–150). The study is registered in 
the Dutch Trial Registry (NL7394).
The HAPPO study team invites colleagues who are 
interested in collaboration or data sharing to contact the 
principal investigators at  HAPPO. studie@ erasmusmc. nl.
Results of the study will be disseminated to healthcare 
professionals and to scientific and industrial peers through 
events, professional organisations and publications in 
peer- reviewed (preferably open- access) journals as well as 
presentations at scientific congresses. Also, results will be 
communicated to women who wish to become pregnant 
and women who experienced pregnancy complications 
by informing patient associations and by dissemination 
via (social) media.
FuTuRE IMPlICATIonS
The results of this study will provide more understanding 
of longitudinal maternal haemodynamic adaptation to 
pregnancy in relation to utero(placental) vascular devel-
opment and its associations with subsequent pregnancy 
outcome. If we succeed to establish an association between 
maternal haemodynamic adaptation to pregnancy and 
subsequent pregnancy outcome, a larger cohort study in 
nulliparous women will be needed to investigate causal 
relationships between haemodynamic adaptation to preg-
nancy and placenta- related outcomes. Hereby, starting 
points for future possibilities to optimise cardiovascular 
and placental health by interventions in clinical valida-
tion studies will arise. This will enable the development 
of more accurate, personalised prevention and treatment 
strategies for women with high- risk pregnancies, from 
the preconception period onwards. Thereby, we aim to 
reduce subsequent maternal and perinatal morbidity and 
mortality in the future, eventually leading to life- long 
reduced risks and costs of cardiovascular diseases.
Author affiliations
1Department of Obstetrics and Gynecology, Erasmus MC, Rotterdam, The 
Netherlands
2Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands
3Department of Intensive Care Adults, Erasmus MC, Rotterdam, The Netherlands
4Department of Anesthesiology & Intensive Care Medicine, Human Physiology and 
Pharmacology Lab (HPPL), Duke Medicine, Durham, North Carolina, USA
5Department of Biostatistics, Erasmus MC, Rotterdam, The Netherlands
6Department of Pathology, Erasmus MC, Rotterdam, The Netherlands
Twitter Jeroen Molinger @JeroenMolinger1
Contributors The rationale and design of the study were conceived by JMJC, 
JJD, JWRH, RST and MPHK. AEB, JM and AHJK contribute their invaluable 
practical expertise and SPW his excellent statistical expertise. RCB is the executive 
researcher, supervised by JMJC, AF and MPHK. MPHK is the principle investigator of 
the study and responsible for all aspects of the study. RCB and MPHK prepared the 
first draft of the protocol. All authors have read and approved the final manuscript.
Funding This work is supported by an Erasmus MC Fellowship Grant (2017) and 
a Peter Joseph Pappas Research Grant from the Preeclampsia Foundation (2019), 
both awarded to MPHK.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
oRCId ids
Rianne C Bijl http:// orcid. org/ 0000- 0002- 0914- 3206
Jolien W Roos- Hesselink http:// orcid. org/ 0000- 0002- 6770- 3830
Maria P H Koster https:// orcid. org/ 0000- 0002- 4786- 0361
REFEREnCES
 1 Anon. ACOG practice Bulletin No. 202: gestational hypertension and 
preeclampsia. Obstet Gynecol 2019;133:e1–25.
 2 Anon. ACOG practice Bulletin No. 204: fetal growth restriction. 
Obstet Gynecol 2019;133:e97–109.
 3 Steegers EAP, von Dadelszen P, Duvekot JJ, et al. Pre- Eclampsia. 
The Lancet 2010;376:631–44.
 4 Bellamy L, Casas J- P, Hingorani AD, et al. Pre- Eclampsia and risk of 
cardiovascular disease and cancer in later life: systematic review and 
meta- analysis. BMJ 2007;335.
 5 Veerbeek JHW, Hermes W, Breimer AY, et al. Cardiovascular disease 
risk factors after early- onset preeclampsia, late- onset preeclampsia, 
and pregnancy- induced hypertension. Hypertension 2015;65:600–6.
 6 Grandi SM, Filion KB, Yoon S, et al. Cardiovascular disease- related 
morbidity and mortality in women with a history of pregnancy 
complications. Circulation 2019;139:1069–79.
 7 Townsend R, Khalil A, Premakumar Y, et al. Prediction of 
pre‐eclampsia: review of reviews. Ultrasound Obstet Gynecol 
2019;54:16–27.
 8 Lamain- de Ruiter M, Kwee A, Naaktgeboren CA, et al. External 
validation of prognostic models for preeclampsia in a Dutch 
multicenter prospective cohort. Hypertension in Pregnancy 
2019;38:78–88.
 9 Cornette J, Roos- Hesselink JW. Normal cardiovascular adaptation 
to pregnancy. in: Stergiopoulos K, brown dl, EDS. evidence- based 
cardiology consult. London: Springer London, 2014: 423–32.
 10 Schannwell CM, Zimmermann T, Schneppenheim M, et al. Left 
ventricular hypertrophy and diastolic dysfunction in healthy pregnant 
women. Cardiology 2002;97:73–8.
4300.7802.430. Protected by copyright.
 o
n
 N
ovem
ber 21, 2019 at Erasm
us M
edical / X51
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-033083 on 10 November 2019. Downloaded from 
7Bijl RC, et al. BMJ Open 2019;9:e033083. doi:10.1136/bmjopen-2019-033083
Open access
 11 Bosio PM, McKenna PJ, Conroy R, et al. Maternal central 
hemodynamics in hypertensive disorders of pregnancy. Obstet 
Gynecol 1999;94:978–84.
 12 Bamfo J, Kametas NA, Turan O, et al. Maternal cardiac function in 
fetal growth restriction. BJOG 2006;113:784–91.
 13 Mannaerts D, Faes E, Goovaerts I, et al. Flow- Mediated dilation 
and peripheral arterial tonometry are disturbed in preeclampsia and 
reflect different aspects of endothelial function. Am J Physiol Regul 
Integr Comp Physiol 2017;313:R518–25.
 14 Osman MW, Nath M, Breslin E, et al. Association between arterial 
stiffness and wave reflection with subsequent development 
of placental- mediated diseases during pregnancy: findings 
of a systematic review and meta- analysis. J Hypertens 
2018;36:1005–14.
 15 Eastabrook G, Aksoy T, Bedell S, et al. Preeclampsia biomarkers: 
an assessment of maternal cardiometabolic health. Pregnancy 
Hypertens 2018;13:204–13.
 16 Sattar N, Greer IA. Pregnancy complications and maternal 
cardiovascular risk: opportunities for intervention and screening? 
BMJ 2002;325:157–60.
 17 Thilaganathan B, Kalafat E. Cardiovascular system in preeclampsia 
and beyond. Hypertension 2019;73:522–31.
 18 Meah VL, Cockcroft JR, Backx K, et al. Cardiac output and related 
haemodynamics during pregnancy: a series of meta- analyses. Heart 
2016;102:518–26.
 19 Mahendru AA, Everett TR, Wilkinson IB, et al. Maternal 
cardiovascular changes from pre- pregnancy to very early pregnancy. 
J Hypertens 2012;30:2168–72.
 20 Mahendru AA, Foo FL, McEniery CM, et al. Change in maternal 
cardiac output from preconception to mid- pregnancy is associated 
with birth weight in healthy pregnancies. Ultrasound Obstet Gynecol 
2017;49:78–84.
 21 Foo FL, Mahendru AA, Masini G, et al. Association between 
prepregnancy cardiovascular function and subsequent preeclampsia 
or fetal growth restriction. Hypertension 2018;72:442–50.
 22 Ghossein- Doha C, Spaanderman MEA, Al Doulah R, et al. Maternal 
cardiac adaptation to subsequent pregnancy in formerly pre- 
eclamptic women according to recurrence of pre- eclampsia. 
Ultrasound Obstet Gynecol 2016;47:96–103.
 23 Regnault TRH, Galan HL, Parker TA, et al. Placental development 
in normal and compromised Pregnancies— a review. Placenta 
2002;23:S119–29.
 24 Burton GJ, Jauniaux E. Pathophysiology of placental- derived fetal 
growth restriction. Am J Obstet Gynecol 2018;218:S745–61.
 25 Burton GJ, Charnock- Jones DS, Jauniaux E. Regulation of 
vascular growth and function in the human placenta. Reproduction 
2009;138:895–902.
 26 Fisher SJ. Why is placentation abnormal in preeclampsia? Am J 
Obstet Gynecol 2015;213:S115–22.
 27 Lockwood CJ, Krikun G, Caze R, et al. Decidual Cell- expressed 
Tissue Factor in Human Pregnancy and Its Involvement in 
Hemostasis and Preeclampsia- related Angiogenesis. Ann N Y Acad 
Sci 2008;1127:67–72.
 28 Predoi CG, Grigoriu C, Vladescu R, et al. Placental damages in 
preeclampsia - from ultrasound images to histopathological findings. 
J Med Life 2015;8:62–5.
 29 Travaglino A, Raffone A, Saccone G, et al. Placental morphology, 
apoptosis, angiogenesis and epithelial mechanisms in early- onset 
preeclampsia. Eur J Obstet Gynecol Reprod Biol 2019;234:200–6.
 30 Steegers- Theunissen RPM, Verheijden- Paulissen JJFM, van Uitert 
EM, et al. Cohort profile: the Rotterdam periconceptional cohort 
(predict study). Int J Epidemiol 2016;45:374–81.
 31 Gordijn SJ, Beune IM, Thilaganathan B, et al. Consensus definition 
of fetal growth restriction: a Delphi procedure. Ultrasound Obstet 
Gynecol 2016;48:333–9.
 32 de Koning L, Merchant AT, Pogue J, et al. Waist circumference 
and waist- to- hip ratio as predictors of cardiovascular events: 
meta- regression analysis of prospective studies. Eur Heart J 
2007;28:850–6.
 33 Cornette J, Laker S, Jeffery B, et al. Validation of maternal cardiac 
output assessed by transthoracic echocardiography against 
pulmonary artery catheterization in severely ill pregnant women: 
prospective comparative study and systematic review. Ultrasound 
Obstet Gynecol 2017;49:25–31.
 34 Bijl RC, Valensise H, Novelli GP, et al. Methods and considerations 
concerning cardiac output measurement in pregnant women: 
recommendations of the International Working group on maternal 
hemodynamics. Ultrasound Obstet Gynecol 2019;54:35–50.
 35 Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations 
for the Evaluation of Left Ventricular Diastolic Function by 
Echocardiography: An Update from the American Society of 
Echocardiography and the European Association of Cardiovascular 
Imaging. J Am Soc Echocardiogr 2016;29:277–314.
 36 Teichholz LE, Cohen MV, Sonnenblick EH, et al. Study of left 
ventricular geometry and function by B- scan ultrasonography in 
patients with and without asynergy. N Engl J Med 1974;291:1220–6.
 37 Yvonne- Tee GB, Rasool AHG, Halim AS, et al. Reproducibility of 
different laser Doppler fluximetry parameters of postocclusive 
reactive hyperemia in human forearm skin. J Pharmacol Toxicol 
Methods 2005;52:286–92.
 38 Tew GA, Klonizakis M, Crank H, et al. Comparison of laser speckle 
contrast imaging with laser Doppler for assessing microvascular 
function. Microvasc Res 2011;82:326–32.
 39 Papaioannou TG, Karageorgopoulou TD, Sergentanis TN, et al. 
Accuracy of commercial devices and methods for noninvasive 
estimation of aortic systolic blood pressure a systematic review 
and meta- analysis of invasive validation studies. J Hypertens 
2016;34:1237–48.
 40 Grillo A, Parati G, Rovina M, et al. Short- Term repeatability of 
noninvasive aortic pulse wave velocity assessment: comparison 
between methods and devices. Am J Hypertens 2018;31:80–8.
 41 Hametner B, Wassertheurer S, Kropf J, et al. Oscillometric estimation 
of aortic pulse wave velocity: comparison with intra- aortic catheter 
measurements. Blood Press Monit 2013;18:173–6.
 42 Tanaka H, Monahan KD, Seals DR. Age- predicted maximal heart rate 
revisited. J Am Coll Cardiol 2001;37:153–6.
 43 Evenson KR, Barakat R, Brown WJ, et al. Guidelines for physical 
activity during pregnancy: comparisons from around the world. Am J 
Lifestyle Med 2014;8:102–21.
 44 Kuc S, Wortelboer EJ, van Rijn BB, et al. Evaluation of 7 serum 
biomarkers and uterine artery Doppler ultrasound for first- trimester 
prediction of preeclampsia: a systematic review. Obstet Gynecol 
Surv 2011;66:225–39.
 45 Reijnders IF, Mulders AGMGJ, Koster MPH, et al. New imaging 
markers for preconceptional and first- trimester utero- placental 
vascularization. Placenta 2018;61:96–102.
 46 Rousian M, Koster MPH, Mulders AGMGJ, et al. Virtual reality 
imaging techniques in the study of embryonic and early placental 
health. Placenta 2018;64:S29–35.
 47 Pooh RK, Maeda K, Kurjak A, et al. 3D/4D sonography – any safety 
problem. J Perinat Med 2016;44:125–9.
 48 Barnett SB, Maulik D, International Perinatal Doppler Society. 
Guidelines and recommendations for safe use of Doppler ultrasound 
in perinatal applications. J Matern Fetal Med 2001;10:75–84.
 49 Veerbeek JHW, Post Uiterweer ED, Nikkels PGJ, et al. Biopsy 
techniques to study the human placental bed. Placenta 
2015;36:775–82.
 50 Veerbeek JHW, Brouwers L, Koster MPH, et al. Spiral artery 
remodeling and maternal cardiovascular risk: the spiral artery 
remodeling (SPAR) study. J Hypertens 2016;34:1570–7.
 51 Melchiorre K, Sharma R, Khalil A, et al. Maternal cardiovascular 
function in normal pregnancy: evidence of maladaptation to chronic 
volume overload. Hypertension 2016;67:754–62.
 52 Gagliardi G, Tiralongo GM, LoPresti D, et al. Screening for pre- 
eclampsia in the first trimester: role of maternal hemodynamics and 
bioimpedance in non- obese patients. Ultrasound Obstet Gynecol 
2017;50:584–8.
 53 Green P, MacLeod CJ, MacLeod Catriona J. SIMR : an R package 
for power analysis of generalized linear mixed models by simulation. 
Methods in Ecology and Evolution 2016;7:493–8.
 54 van Oostwaard MF, Langenveld J, Schuit E, et al. Recurrence of 
hypertensive disorders of pregnancy: an individual patient data 
metaanalysis. Am J Obstet Gynecol 2015;212:624.e1–624.e17.
 55 Voskamp BJ, Kazemier BM, Ravelli ACJ, et al. Recurrence of small- 
for- gestational- age pregnancy: analysis of first and subsequent 
singleton pregnancies in the Netherlands. Am J Obstet Gynecol 
2013;208:374.e1–374.e6.
 56 Mostello D, Catlin TK, Roman L, et al. Preeclampsia in the parous 
woman: who is at risk? Am J Obstet Gynecol 2002;187:425–9.
 57 Evers JLH. Female subfertility. The Lancet 2002;360:151–9.
 58 van Balen F, Verdurmen JE, Ketting E. Age, the desire to have 
a child and cumulative pregnancy rate. Human Reproduction 
1997;12:623–7.
 59 Ammon Avalos L, Galindo C, Li D- K. A systematic review to calculate 
background miscarriage rates using life table analysis. Birth Defects 
Res A Clin Mol Teratol 2012;94:417–23.
 60 Foo FL, Collins A, McEniery CM, et al. Preconception and early 
pregnancy maternal haemodynamic changes in healthy women in 
relation to pregnancy viability. Hum Reprod 2017;32:985–92.
 61 Bamfo JEAK, Kametas NA, Chambers JB, et al. Maternal cardiac 
function in normotensive and pre- eclamptic intrauterine growth 
restriction. Ultrasound Obstet Gynecol 2008;32:682–6.
4300.7802.430. Protected by copyright.
 o
n
 N
ovem
ber 21, 2019 at Erasm
us M
edical / X51
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-033083 on 10 November 2019. Downloaded from 
8 Bijl RC, et al. BMJ Open 2019;9:e033083. doi:10.1136/bmjopen-2019-033083
Open access 
 62 De Paco C, Kametas N, Rencoret G, et al. Maternal cardiac 
output between 11 and 13 weeks of gestation in the prediction of 
preeclampsia and small for gestational age. Obstetrics & Gynecology 
2008;111:292–300.
 63 Ferrazzi E, Stampalija T, Monasta L, et al. Maternal hemodynamics: a 
method to classify hypertensive disorders of pregnancy. Am J Obstet 
Gynecol 2018;218:124.e1–124.e11.
 64 Khalil A, Akolekar R, Syngelaki A, et al. Maternal hemodynamics in 
normal pregnancies at 11–13 Weeks’ gestation. Fetal Diagn Ther 
2012;32:179–85.
 65 Mannaerts D, Faes E, Gielis J, et al. Oxidative stress and endothelial 
function in normal pregnancy versus pre- eclampsia, a combined 
longitudinal and case control study. BMC Pregnancy Childbirth 
2018;18:60.
 66 Verlohren S, Perschel FH, Thilaganathan B, et al. Angiogenic markers 
and cardiovascular indices in the prediction of hypertensive disorders 
of pregnancy. Hypertension 2017;69:1192–7.
4300.7802.430. Protected by copyright.
 o
n
 N
ovem
ber 21, 2019 at Erasm
us M
edical / X51
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-033083 on 10 November 2019. Downloaded from 
